Indication
Chemoradiotherapy
11 clinical trials
3 products
9 drugs
Clinical trial
PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II TrialStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Drug
PD-1 inhibitorsClinical trial
Evaluation of Concomitant Chemo-radiotherapy With Cisplatin vs Gemcitabine as the First Line of Treatment in Patients With Locally Advanced Cervical Cancer, With Comorbidities and Preserved Renal Function, is a Phase III Clinical Trial.Status: Recruiting, Estimated PCD: 2026-11-30
Drug
GemcitabineDrug
CisplatinClinical trial
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma After Failure of Chemotherapy：A Phase II StudyStatus: Recruiting, Estimated PCD: 2025-12-31
Product
NimotuzumabClinical trial
Nimotuzumab Concurrent With Chemoradiotherapy for Elderly or Malnourished Patients With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II StudyStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)Status: Active (not recruiting), Estimated PCD: 2024-03-30
Drug
TiragolumabDrug
AN0025Clinical trial
Tislelizumab (Anti-PD-1) Combined With Definitive Chemoradiotherapy in Recurrent Cervical Cancer (PILOT-2020-511): a Single-arm, Phase 2 TrialStatus: Recruiting, Estimated PCD: 2023-12-31
Product
Treatment GroupClinical trial
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Esophageal Squamous Cell Carcinoma: A Randomized, Multi-center Phase II Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Drug
PD-1 antibodyClinical trial
Non-OpeRative MANagement of Rectal Cancer Patients Who Had Clinical Complete Response After Pre-operative Chemo-raDiotherapYStatus: Recruiting, Estimated PCD: 2024-12-31
Drug
UTD1Clinical trial
A Prospective Randomized Controlled Trial for Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy in the Treatment of Advanced Cervical Cancer at 2018 FIGO StagingStatus: Recruiting, Estimated PCD: 2025-06-30
Product
PaclitaxelClinical trial
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Squamous Cell Carcinoma Based on Nutritional Risk Screening Score (NRS2002)Status: Completed, Estimated PCD: 2022-12-30
Drug
NimotuzumabClinical trial
Toripalimab Combined With Definitive Chemoradiotherapy for Locally Advanced Cervical Squamous Cell Carcinoma PatientsStatus: Recruiting, Estimated PCD: 2028-12-31
Drug
S-1